13 research outputs found
Le genre est-il un facteur associé à la mise sous traitement antirétroviral au Centre de Traitement Ambulatoire de Brazzaville ?
No full textPerformance of World Health Organization (WHO) Immunological Response to Predict Virological Failure in Patients With Severe Versus Moderate Immunosuppression at Antiretroviral Therapy Initiation
No full textMolecular Characterization of HIV Type 1 in Brazzaville, Republic of Congo, and First Data on Resistance to Antiretroviral Drugs
No full textAssociation between depressive symptoms and adherence among adolescents living with HIV in the Republic of Congo
No full textThe increasing availability of antiretroviral therapy (ART) worldwide is yet to result in decreasing HIV-related mortality among adolescents (10–19 years old) living with HIV (ALHIV) in part because of poor adherence. the poor adherence might itself be due to high level of depression. We assess the prevalence of depressive symptomatology and it's associated with adherence among ALHIV receiving ART care in Brazzaville and Pointe Noire, Republic of Congo (RoC). Adolescents aged 10 to 19 years, on antiretroviral therapy (ART), followed in the two Ambulatory Treatment Centers (ATC) in Brazzaville and Pointe Noire, RoC were included in this cross-sectional study. From April 19 to July 9, 2018, participants were administered face to face interviews using a standardized questionnaire that included the nine-item Patient Health Questionnaire (PHQ-9). Participants who reported failing to take their ART more than twice in the 7 days preceding the interview were classified as non-adherent. Bivariate and multivariable log-binomial models were used to estimate the prevalence ratio (PR) and 95% confidence interval (95%CI) assessing the strength of association between predictors and presence of depressive symptoms (PHQ-9 score ≥9). Overall, 135 adolescents represented 50% of ALHIV in active care at the 2 clinics were interviewed. Of those, 67 (50%) were male, 81 (60%) were 15 to 19 years old, 124 (95%) had been perinatally infected, and 71 (53%) knew their HIV status. Depressive symptoms were present in 52 (39%) participants and 78 (58%) were adherent. In univariate analyses, the prevalence of depressive symptoms was relative higher among participants who were not adherent compared to those who were (73% vs 33%; PR: 2.20 [95%CI: 1.42–3.41]). In multivariate analysis, after adjustment for report of been sexually active, alcohol drinking, age category (10–14 and 15–19), not in school, loss of both parents, the association between depression and adherence was strengthened (PR: 2.06 [95%CI: 1.23–3.45]). The prevalence of depressive symptoms in adolescents living with HIV is high and was strongly associated with poor adherence even after adjustment of potential confounders. Efforts to scale-up access to screening and management of depression among ALHIV in sub-Saharan is needed for them to realize the full of ART
Characteristics of Central Africa IeDEA sites.
No full textCharacteristics of Central Africa IeDEA sites.</p
Changes in clinic environment or operations at Central Africa IeDEA sites, by country, Round 2 (October 2020—February 2021).
No full textART: Antiretroviral therapy; IeDEA: International epidemiology Databases to Evaluate AIDS; PrEP: Pre-exposure prophylaxis. ** Sites where the service was not available prior to the COVID-19 pandemic excluded from denominator. (DOCX)</p
Changes in HIV-related services and capacity at Central Africa IeDEA sites, 2020–2021.
No full textChanges in HIV-related services and capacity at Central Africa IeDEA sites, 2020–2021.</p
Changes in clinic environment or operations at Central Africa IeDEA sites, by country, Round 1 (June—July 2020).
No full textART: Antiretroviral therapy; IeDEA: International epidemiology Databases to Evaluate AIDS. ** Sites where the service was not available prior to the COVID-19 pandemic excluded from denominator. (DOCX)</p
Effects of COVID-19 on HIV-related services and capacity at Central Africa IeDEA sites, by country, Round 2 (Oct 2020—Feb 2021).
No full textART: Antiretroviral therapy; IeDEA: International epidemiology Databases to Evaluate AIDS; PrEP: Pre-exposure prophylaxis. ** Sites where the service was not available prior to the COVID-19 pandemic excluded from denominator. (DOCX)</p
COVID-19 pandemic-related changes in clinic environment or operations at Central Africa IeDEA sites, 2020–2021.
No full textCOVID-19 pandemic-related changes in clinic environment or operations at Central Africa IeDEA sites, 2020–2021.</p
